BioMedNewsBreaks Archive - Page 194 of 224

WednesdayJan 06, 2021 10:50 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Participation in Two Upcoming Virtual Events

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, will be presenting at two investor conferences in January: the SNN Network Canada Virtual Event and the H.C. Wainwright Bioconnect 2021 Virtual Conference. Company founder and CEO Dr. Jack Regan will represent LexaGene at both events. The SNN Network Canada Virtual Event is scheduled for Thursday, Jan. 7, 2021; LexaGene’s live presentation is slated to begin at 1:30 p.m. ET. Those interested can find the webcast presentation on the conference event platform under the agenda tab following the event. The H.C. Wainwright Bioconnect…

WednesdayJan 06, 2021 10:43 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with registered investors and pharmaceutical companies. Sapirstein will be available to provide an overview of the company’s business and clinical development programs, as well as discuss anticipated 2021 milestones. Interested parties should visit https://ibn.fm/bNYP3 to register for the event. To view the full press release, visit…

WednesdayJan 06, 2021 9:31 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be available on-demand throughout the event from Jan. 11-14, 2021, starting at 6:00 a.m. ET. In addition, a webcast of the presentation will be available via the IR section of the company’s website and will be archived and accessible for at least 90 days. To view…

WednesdayJan 06, 2021 8:30 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering from OSA around the world, it is the most predominant diseases, and can cause life-threatening high blood pressure, heart failure, stroke and other health problems. and life-threatening diseases. “We believe that Vivos’ sleep-specific AireO2 patient…

TuesdayJan 05, 2021 2:02 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Assists with Well-Informed Decisions

United Medical Equipment (“UME”) has created a powerful app designed for health-care professionals, caregivers, students and family members who are providing direct and indirect patient care and education. Providing critical information and access to real-time tools, UME’s Medication Management app features more than a dozen different functionalities. The app enables access to a library for up-to-date information on medications and their indications, dosage, side effects, etc.; identification tools for medications not contained in original packaging; conversion systems for metric-U.S./Imperial quantities that includes weight, temperature, volume, and height; dosage converter for active medications/treatments; and much more. A recent article discussing this…

TuesdayJan 05, 2021 12:42 pm

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in Equity Research Report

INmune Bio (NASDAQ: INMB), a biotechnology company focused on modulating components of the innate immune system to treat cancers and chronic neurological diseases, was featured in an equity research report by Quantum Media Group LLC. Quantum announced its coverage initiative on INmune Bio on Dec. 30, 2020, and provided details on its research paper that discusses the paradigm shift in Alzheimer’s research and treatment strategies in development, rejecting the decades-long approach by the pharmaceutical industry and academia at large. Quantum believes that INmune Bio’s XPro1595 is potentially a best-in-class Alzheimer’s drug, and further believes that the readout for the upcoming…

TuesdayJan 05, 2021 11:30 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to investors, financial and industry analysts, registered brokers and financial writers. Those introductions would be made with the intent to provide interested individuals and groups with information about POAI’s business strategy, developments and accomplishments. The announcement also noted that Landon Capital would assist POAI in the…

TuesdayJan 05, 2021 10:39 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters into Agreement with Fortune 500 Subsidiary to Provide Digital Therapeutics Solution

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has been selected by a subsidiary of a U.S.-based Fortune 500 technology and engineering company to provide its digital therapeutics solution to eligible employees. DarioHealth’s partnership with Vitality Group made this agreement possible, which is DarioHealth’s first client in the self-insured employer market. One of the largest wellness companies in the world, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and their organizations; an estimated 20 million people in 26 markets engage in the Vitality program. Under the announced agreement, members…

TuesdayJan 05, 2021 10:05 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a summary of the company’s business and clinical-development programs to any interested parties. His presentation will also include expected 2021 highlights. In addition, Sapirstein will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies. The multiday event is scheduled for Jan. 6–8 and 11–14, 2021. To register for the event, visit https://ibn.fm/JBmMH To view the full press release, visit…

MondayJan 04, 2021 2:34 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Participation in Two Upcoming Virtual Events

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Assists with Well-Informed Decisions

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in Equity Research Report

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters into Agreement with Fortune 500 Subsidiary to Provide Digital Therapeutics Solution

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search